Petach Tikvah, Israel – May 15^th, 2025

Interna Therapeutics (“Interna^TX”), a biopharmaceutical company pioneering a universal platform for the intracellular delivery of macromolecule drugs, today announced the successful completion of its Phase I clinical trial of an intranasal siRNA therapy for COVID-19. The study was conducted at the Hadassah Clinical Research Center in Jerusalem, Israel.

Interna’s investigational therapy is an MNM-siRNA drug targeting a conserved gene of SARS-CoV-2, designed for convenient self-administration at home. It is being developed for pre-exposure prophylaxis, post-exposure prophylaxis, and therapeutic treatment. Building on robust preclinical data that demonstrated both efficacy and safety, Interna advanced the program into human evaluation following GMP manufacturing, regulatory approval from the Israel Ministry of Health, and study performance at a leading Israeli clinical center.

The Phase I trial was a randomized, double-blind, placebo-controlled, single-center study. It evaluated single and repeated intranasal doses (up to twice daily for five days) across ascending dose levels in healthy adult volunteers. The study objectives were to assess safety, tolerability, and confirm the absence of systemic exposure when the MNM-siRNA COVID-19 therapy is administered intranasally.

Dosing began on September 3, 2024, and the trial was successfully completed in Q2 2025, meeting all planned milestones.